Report Detail
Global Hypertensive Heart Disease Drug Market Growth (Status and Outlook) 2022-2028
- RnM4496060 |
- 30 November, 2022 |
- Global |
- 111 Pages |
- LPI(LP Information) |
- Medical Industry
The global market for Hypertensive Heart Disease Drug is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Hypertensive Heart Disease Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Hypertensive Heart Disease Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Hypertensive Heart Disease Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Hypertensive Heart Disease Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Hypertensive Heart Disease Drug players cover Abbott Laboratories, AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH and Bayer AG, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Hypertensive Heart Disease Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Hypertensive Heart Disease Drug market, with both quantitative and qualitative data, to help readers understand how the Hypertensive Heart Disease Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Hypertensive Heart Disease Drug market and forecasts the market size by Type (Calcium Channel Blockers, Diuretics and Beta Blockers), by Application (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Calcium Channel Blockers
Diuretics
Beta Blockers
ACE Inhibitors
Potassium Replacements
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Abbott Laboratories
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Boehringer Ingelheim International GmbH
Bayer AG
Eiger Biopharmaceuticals, Inc.
Daiichi Sankyo Co., Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline PLC
F. Hoffmann-La Roche Ltd.
Johnson & Johnson Services, Inc.
Lupin Pharmaceuticals, 13. Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi SA
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Co. Ltd.
United Therapeutics Corp.
Northern Therapeutics Inc.
Chapter Introduction
Chapter 1: Scope of Hypertensive Heart Disease Drug, Research Methodology, etc.
Chapter 2: Executive Summary, global Hypertensive Heart Disease Drug market size and CAGR, Hypertensive Heart Disease Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Hypertensive Heart Disease Drug revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Hypertensive Heart Disease Drug revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Hypertensive Heart Disease Drug market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Abbott Laboratories, AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Bayer AG, Eiger Biopharmaceuticals, Inc., Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc. and GlaxoSmithKline PLC, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Hypertensive Heart Disease Drug Market Size 2017-2028
- 2.1.2 Hypertensive Heart Disease Drug Market Size CAGR by Region 2017 VS 2022 VS 2028
- 2.2 Hypertensive Heart Disease Drug Segment by Type
- 2.2.1 Calcium Channel Blockers
- 2.2.2 Diuretics
- 2.2.3 Beta Blockers
- 2.2.4 ACE Inhibitors
- 2.2.5 Potassium Replacements
- 2.3 Hypertensive Heart Disease Drug Market Size by Type
- 2.3.1 Hypertensive Heart Disease Drug Market Size CAGR by Type (2017 VS 2022 VS 2028)
- 2.3.2 Global Hypertensive Heart Disease Drug Market Size Market Share by Type (2017-2022)
- 2.4 Hypertensive Heart Disease Drug Segment by Application
- 2.4.1 Hospital Pharmacies
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Pharmacies
- 2.5 Hypertensive Heart Disease Drug Market Size by Application
- 2.5.1 Hypertensive Heart Disease Drug Market Size CAGR by Application (2017 VS 2022 VS 2028)
- 2.5.2 Global Hypertensive Heart Disease Drug Market Size Market Share by Application (2017-2022)
3 Hypertensive Heart Disease Drug Market Size by Player
- 3.1 Hypertensive Heart Disease Drug Market Size Market Share by Players
- 3.1.1 Global Hypertensive Heart Disease Drug Revenue by Players (2020-2022)
- 3.1.2 Global Hypertensive Heart Disease Drug Revenue Market Share by Players (2020-2022)
- 3.2 Global Hypertensive Heart Disease Drug Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Hypertensive Heart Disease Drug by Regions
- 4.1 Hypertensive Heart Disease Drug Market Size by Regions (2017-2022)
- 4.2 Americas Hypertensive Heart Disease Drug Market Size Growth (2017-2022)
- 4.3 APAC Hypertensive Heart Disease Drug Market Size Growth (2017-2022)
- 4.4 Europe Hypertensive Heart Disease Drug Market Size Growth (2017-2022)
- 4.5 Middle East & Africa Hypertensive Heart Disease Drug Market Size Growth (2017-2022)
5 Americas
- 5.1 Americas Hypertensive Heart Disease Drug Market Size by Country (2017-2022)
- 5.2 Americas Hypertensive Heart Disease Drug Market Size by Type (2017-2022)
- 5.3 Americas Hypertensive Heart Disease Drug Market Size by Application (2017-2022)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Hypertensive Heart Disease Drug Market Size by Region (2017-2022)
- 6.2 APAC Hypertensive Heart Disease Drug Market Size by Type (2017-2022)
- 6.3 APAC Hypertensive Heart Disease Drug Market Size by Application (2017-2022)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Hypertensive Heart Disease Drug by Country (2017-2022)
- 7.2 Europe Hypertensive Heart Disease Drug Market Size by Type (2017-2022)
- 7.3 Europe Hypertensive Heart Disease Drug Market Size by Application (2017-2022)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Hypertensive Heart Disease Drug by Region (2017-2022)
- 8.2 Middle East & Africa Hypertensive Heart Disease Drug Market Size by Type (2017-2022)
- 8.3 Middle East & Africa Hypertensive Heart Disease Drug Market Size by Application (2017-2022)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Hypertensive Heart Disease Drug Market Forecast
- 10.1 Global Hypertensive Heart Disease Drug Forecast by Regions (2023-2028)
- 10.1.1 Global Hypertensive Heart Disease Drug Forecast by Regions (2023-2028)
- 10.1.2 Americas Hypertensive Heart Disease Drug Forecast
- 10.1.3 APAC Hypertensive Heart Disease Drug Forecast
- 10.1.4 Europe Hypertensive Heart Disease Drug Forecast
- 10.1.5 Middle East & Africa Hypertensive Heart Disease Drug Forecast
- 10.2 Americas Hypertensive Heart Disease Drug Forecast by Country (2023-2028)
- 10.2.1 United States Hypertensive Heart Disease Drug Market Forecast
- 10.2.2 Canada Hypertensive Heart Disease Drug Market Forecast
- 10.2.3 Mexico Hypertensive Heart Disease Drug Market Forecast
- 10.2.4 Brazil Hypertensive Heart Disease Drug Market Forecast
- 10.3 APAC Hypertensive Heart Disease Drug Forecast by Region (2023-2028)
- 10.3.1 China Hypertensive Heart Disease Drug Market Forecast
- 10.3.2 Japan Hypertensive Heart Disease Drug Market Forecast
- 10.3.3 Korea Hypertensive Heart Disease Drug Market Forecast
- 10.3.4 Southeast Asia Hypertensive Heart Disease Drug Market Forecast
- 10.3.5 India Hypertensive Heart Disease Drug Market Forecast
- 10.3.6 Australia Hypertensive Heart Disease Drug Market Forecast
- 10.4 Europe Hypertensive Heart Disease Drug Forecast by Country (2023-2028)
- 10.4.1 Germany Hypertensive Heart Disease Drug Market Forecast
- 10.4.2 France Hypertensive Heart Disease Drug Market Forecast
- 10.4.3 UK Hypertensive Heart Disease Drug Market Forecast
- 10.4.4 Italy Hypertensive Heart Disease Drug Market Forecast
- 10.4.5 Russia Hypertensive Heart Disease Drug Market Forecast
- 10.5 Middle East & Africa Hypertensive Heart Disease Drug Forecast by Region (2023-2028)
- 10.5.1 Egypt Hypertensive Heart Disease Drug Market Forecast
- 10.5.2 South Africa Hypertensive Heart Disease Drug Market Forecast
- 10.5.3 Israel Hypertensive Heart Disease Drug Market Forecast
- 10.5.4 Turkey Hypertensive Heart Disease Drug Market Forecast
- 10.5.5 GCC Countries Hypertensive Heart Disease Drug Market Forecast
- 10.6 Global Hypertensive Heart Disease Drug Forecast by Type (2023-2028)
- 10.7 Global Hypertensive Heart Disease Drug Forecast by Application (2023-2028)
11 Key Players Analysis
- 11.1 Abbott Laboratories
- 11.1.1 Abbott Laboratories Company Information
- 11.1.2 Abbott Laboratories Hypertensive Heart Disease Drug Product Offered
- 11.1.3 Abbott Laboratories Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.1.4 Abbott Laboratories Main Business Overview
- 11.1.5 Abbott Laboratories Latest Developments
- 11.2 AstraZeneca PLC
- 11.2.1 AstraZeneca PLC Company Information
- 11.2.2 AstraZeneca PLC Hypertensive Heart Disease Drug Product Offered
- 11.2.3 AstraZeneca PLC Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.2.4 AstraZeneca PLC Main Business Overview
- 11.2.5 AstraZeneca PLC Latest Developments
- 11.3 Actelion Pharmaceuticals Ltd.
- 11.3.1 Actelion Pharmaceuticals Ltd. Company Information
- 11.3.2 Actelion Pharmaceuticals Ltd. Hypertensive Heart Disease Drug Product Offered
- 11.3.3 Actelion Pharmaceuticals Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.3.4 Actelion Pharmaceuticals Ltd. Main Business Overview
- 11.3.5 Actelion Pharmaceuticals Ltd. Latest Developments
- 11.4 Boehringer Ingelheim International GmbH
- 11.4.1 Boehringer Ingelheim International GmbH Company Information
- 11.4.2 Boehringer Ingelheim International GmbH Hypertensive Heart Disease Drug Product Offered
- 11.4.3 Boehringer Ingelheim International GmbH Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.4.4 Boehringer Ingelheim International GmbH Main Business Overview
- 11.4.5 Boehringer Ingelheim International GmbH Latest Developments
- 11.5 Bayer AG
- 11.5.1 Bayer AG Company Information
- 11.5.2 Bayer AG Hypertensive Heart Disease Drug Product Offered
- 11.5.3 Bayer AG Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.5.4 Bayer AG Main Business Overview
- 11.5.5 Bayer AG Latest Developments
- 11.6 Eiger Biopharmaceuticals, Inc.
- 11.6.1 Eiger Biopharmaceuticals, Inc. Company Information
- 11.6.2 Eiger Biopharmaceuticals, Inc. Hypertensive Heart Disease Drug Product Offered
- 11.6.3 Eiger Biopharmaceuticals, Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.6.4 Eiger Biopharmaceuticals, Inc. Main Business Overview
- 11.6.5 Eiger Biopharmaceuticals, Inc. Latest Developments
- 11.7 Daiichi Sankyo Co., Ltd.
- 11.7.1 Daiichi Sankyo Co., Ltd. Company Information
- 11.7.2 Daiichi Sankyo Co., Ltd. Hypertensive Heart Disease Drug Product Offered
- 11.7.3 Daiichi Sankyo Co., Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.7.4 Daiichi Sankyo Co., Ltd. Main Business Overview
- 11.7.5 Daiichi Sankyo Co., Ltd. Latest Developments
- 11.8 Gilead Sciences, Inc.
- 11.8.1 Gilead Sciences, Inc. Company Information
- 11.8.2 Gilead Sciences, Inc. Hypertensive Heart Disease Drug Product Offered
- 11.8.3 Gilead Sciences, Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.8.4 Gilead Sciences, Inc. Main Business Overview
- 11.8.5 Gilead Sciences, Inc. Latest Developments
- 11.9 GlaxoSmithKline PLC
- 11.9.1 GlaxoSmithKline PLC Company Information
- 11.9.2 GlaxoSmithKline PLC Hypertensive Heart Disease Drug Product Offered
- 11.9.3 GlaxoSmithKline PLC Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.9.4 GlaxoSmithKline PLC Main Business Overview
- 11.9.5 GlaxoSmithKline PLC Latest Developments
- 11.10 F. Hoffmann-La Roche Ltd.
- 11.10.1 F. Hoffmann-La Roche Ltd. Company Information
- 11.10.2 F. Hoffmann-La Roche Ltd. Hypertensive Heart Disease Drug Product Offered
- 11.10.3 F. Hoffmann-La Roche Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.10.4 F. Hoffmann-La Roche Ltd. Main Business Overview
- 11.10.5 F. Hoffmann-La Roche Ltd. Latest Developments
- 11.11 Johnson & Johnson Services, Inc.
- 11.11.1 Johnson & Johnson Services, Inc. Company Information
- 11.11.2 Johnson & Johnson Services, Inc. Hypertensive Heart Disease Drug Product Offered
- 11.11.3 Johnson & Johnson Services, Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.11.4 Johnson & Johnson Services, Inc. Main Business Overview
- 11.11.5 Johnson & Johnson Services, Inc. Latest Developments
- 11.12 Lupin Pharmaceuticals, 13. Merck KGaA
- 11.12.1 Lupin Pharmaceuticals, 13. Merck KGaA Company Information
- 11.12.2 Lupin Pharmaceuticals, 13. Merck KGaA Hypertensive Heart Disease Drug Product Offered
- 11.12.3 Lupin Pharmaceuticals, 13. Merck KGaA Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.12.4 Lupin Pharmaceuticals, 13. Merck KGaA Main Business Overview
- 11.12.5 Lupin Pharmaceuticals, 13. Merck KGaA Latest Developments
- 11.13 Novartis AG
- 11.13.1 Novartis AG Company Information
- 11.13.2 Novartis AG Hypertensive Heart Disease Drug Product Offered
- 11.13.3 Novartis AG Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.13.4 Novartis AG Main Business Overview
- 11.13.5 Novartis AG Latest Developments
- 11.14 Pfizer Inc.
- 11.14.1 Pfizer Inc. Company Information
- 11.14.2 Pfizer Inc. Hypertensive Heart Disease Drug Product Offered
- 11.14.3 Pfizer Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.14.4 Pfizer Inc. Main Business Overview
- 11.14.5 Pfizer Inc. Latest Developments
- 11.15 Sanofi SA
- 11.15.1 Sanofi SA Company Information
- 11.15.2 Sanofi SA Hypertensive Heart Disease Drug Product Offered
- 11.15.3 Sanofi SA Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.15.4 Sanofi SA Main Business Overview
- 11.15.5 Sanofi SA Latest Developments
- 11.16 Sun Pharmaceutical Industries Ltd.
- 11.16.1 Sun Pharmaceutical Industries Ltd. Company Information
- 11.16.2 Sun Pharmaceutical Industries Ltd. Hypertensive Heart Disease Drug Product Offered
- 11.16.3 Sun Pharmaceutical Industries Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.16.4 Sun Pharmaceutical Industries Ltd. Main Business Overview
- 11.16.5 Sun Pharmaceutical Industries Ltd. Latest Developments
- 11.17 Takeda Pharmaceutical Co. Ltd.
- 11.17.1 Takeda Pharmaceutical Co. Ltd. Company Information
- 11.17.2 Takeda Pharmaceutical Co. Ltd. Hypertensive Heart Disease Drug Product Offered
- 11.17.3 Takeda Pharmaceutical Co. Ltd. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.17.4 Takeda Pharmaceutical Co. Ltd. Main Business Overview
- 11.17.5 Takeda Pharmaceutical Co. Ltd. Latest Developments
- 11.18 United Therapeutics Corp.
- 11.18.1 United Therapeutics Corp. Company Information
- 11.18.2 United Therapeutics Corp. Hypertensive Heart Disease Drug Product Offered
- 11.18.3 United Therapeutics Corp. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.18.4 United Therapeutics Corp. Main Business Overview
- 11.18.5 United Therapeutics Corp. Latest Developments
- 11.19 Northern Therapeutics Inc.
- 11.19.1 Northern Therapeutics Inc. Company Information
- 11.19.2 Northern Therapeutics Inc. Hypertensive Heart Disease Drug Product Offered
- 11.19.3 Northern Therapeutics Inc. Hypertensive Heart Disease Drug Revenue, Gross Margin and Market Share (2020-2022)
- 11.19.4 Northern Therapeutics Inc. Main Business Overview
- 11.19.5 Northern Therapeutics Inc. Latest Developments
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Hypertensive Heart Disease Drug. Industry analysis & Market Report on Hypertensive Heart Disease Drug is a syndicated market report, published as Global Hypertensive Heart Disease Drug Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Hypertensive Heart Disease Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
